The Top 5 Best Immunotherapy Treatments for Lung Cancer in 2025

Recent Trends in Lung Cancer Immunotherapy

Over the past two years, the immunotherapy landscape for lung cancer has shifted toward earlier-line use and personalized combination regimens. Regulatory approvals have expanded for several checkpoint inhibitors in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, biomarker-directed therapies—such as those targeting PD-L1 expression levels and tumor mutational burden—now guide frontline decisions more precisely than ever.

Another notable trend is the rise of bispecific antibodies and cellular therapies in clinical trials. These next-generation agents aim to overcome resistance mechanisms that limit durable responses with standard checkpoint blockade alone.

Background: How Immunotherapy Changed Lung Cancer Care

Immunotherapy works by reactivating the immune system’s ability to recognize and attack cancer cells. Unlike chemotherapy, which directly kills dividing cells, checkpoint inhibitors block proteins (such as PD-1, PD-L1, and CTLA-4) that tumors use to evade immune detection.

• First-generation agents (e.g., PD-1/PD-L1 inhibitors) showed durable responses in a subset of patients with high PD-L1 scores.
• Combination approaches adding chemotherapy or a second immune checkpoint improved outcomes regardless of PD-L1 level.
• Dual immunotherapy (PD-1/CTLA-4 blockade) proved effective for certain histologies, though with increased immune-related side effects.

These advances have made immunotherapy a standard backbone across lines of therapy for appropriate candidates.

User Concerns: Efficacy, Toxicity, and Access

Patients and clinicians weigh multiple factors when selecting among the top immunotherapy options. Concerns often break down into three categories:

• Durability of response: Some treatments show higher rates of long-term remission, while others are better suited for rapid tumor shrinkage needed in symptomatic disease.
• Immune-related adverse events (irAEs): Combinations carry a higher risk of colitis, pneumonitis, or endocrinopathies, requiring proactive monitoring and management.
• Cost and insurance coverage: Access varies by region and payer, with some newer regimens carrying substantially higher out-of-pocket costs unless covered through patient assistance programs or clinical trials.

Shared decision-making should ideally include a discussion of a patient’s performance status, existing autoimmune conditions, and biomarker test results.

Likely Impact of the Top Five Immunotherapy Approaches

While no single treatment is best for all patients, the following five categories represent the most frequently selected strategies in 2025 based on clinical guidelines and real-world evidence:

• PD-1 monotherapy (e.g., nivolumab, pembrolizumab): Remains a frontline standard for NSCLC with PD-L1 ≥50%, offering a favorable toxicity profile and well-characterized long-term data.
• PD-L1 monotherapy (e.g., atezolizumab, durvalumab): Preferred in certain patient subgroups and following chemoradiation for unresectable stage III NSCLC.
• PD-1 plus chemotherapy: Extends benefit to patients with lower PD-L1 expression; broadest approved indication across NSCLC histologies.
• Dual immune checkpoint blockade (PD-1 plus CTLA-4): Used primarily in high-tumor-burden or aggressive disease, though clinicians carefully select candidates due to higher irAE risk.
• PD-L1 plus anti-angiogenic therapy: Approved for first-line treatment of non-squamous NSCLC with certain biomarker profiles, combining immune activation with vascular normalization.

These strategies have collectively improved median overall survival compared to chemotherapy alone by several months to a year or more in appropriate subgroups.

What to Watch Next

The field is moving toward even more precise immunotherapy selection. Key developments to monitor include:

• Biomarker-driven trial results: New data on tumor mutational burden, T-cell infiltration patterns, and circulating tumor DNA may refine which patients benefit most from each regimen.
• Next-generation agents: Bispecific T-cell engagers and personalized neoantigen vaccines are advancing through late-stage trials, with potential to become additional options within five years.
• Sequencing strategies: Research is clarifying optimal order of immunotherapy relative to targeted therapy and chemotherapy to maximize cumulative benefit while minimizing toxicity.
• Real-world evidence: Ongoing registries and claims analyses will provide feedback on how these top five approaches perform across diverse patient populations outside clinical trials.

Stakeholders should expect updated clinical guidelines and potential label expansions within the next 12–18 months based on these emerging data.